copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Immune responses to a HSV-2 polynucleotide immunotherapy COR . . . Genital herpes simplex infection affects more than 500 million people worldwide We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects Here, we present a single
Coridon HSV-2 vaccine shows 100% efficacy - Fierce Pharma Brisbane, Australia-based biotech Coridon has developed a DNA vaccine for herpes simplex virus 2 that showed 100% efficacy in a preclinical trial Thanks to financial backing from Allied
Herpes Vaccine Research - American Sexual Health Association The need for a herpes vaccine is clear: about half a billion people worldwide between the ages of 15-49 have genital herpes infection caused by either HSV-1 or HSV-2, according to the World Health Organization (WHO) In the United States alone, an estimated 1 in 6 adults have genital herpes, with around 300,000 new infections diagnosed each year
Herpes Vaccine Candidates — Vax-Before-Travel Herpes Vaccine Preclinical Development Redbiotec is developing an HSV-2 therapeutic vaccine, also known as immunotherapy Their vaccine program uses T-cell-mediated protection and aims to outperform antivirals With two injections, patients can remain symptom-free for over 12 months
Hope for prevention of herpes through new vaccine - Frazer . . . Coridon Pty Ltd will soon start a Phase I HSV-2 vaccine clinical trial in Brisbane Professor Ian Frazer AC, who said the new technology could eventually prevent and cure the herpes simplex virus (HSV-2), and could also lead to other effective vaccinations for incurable diseases such as HIV AIDS and hepatitis C
An escalating dose study to assess the safety, tolerability . . . ABSTRACT This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice Five escalating doses of the vaccine, COR-1, were given by